# Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory <i>FLT3</i>-Mutated AML

*PRI Rank #9 · Topics and Trends in Most Cited Acute Myeloid Leukemia Research Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/acute-myeloid-leukemia-research/2026/rank-9*

| Field | Value |
| --- | --- |
| Rank | #9 |
| 18m citations | 74 |
| Journal | Journal of Clinical Oncology |
| Year | 2024 |
| DOI | 10.1200/jco.23.01911 |
| Corresponding authors | Nicholas J Short |
| Institution | The University of Texas MD Anderson Cancer Center, United States |

**Ranking page:** [Topics and Trends in Most Cited Acute Myeloid Leukemia Research Papers, Class of 2026](https://pri.pepkio.com/top-papers/acute-myeloid-leukemia-research/2026)

**Paper link:** [10.1200/jco.23.01911](https://doi.org/10.1200/jco.23.01911)

## Topics

Azacitidine · Venetoclax · gilteritinib · FLT3-mutated AML · FLT3-internal tandem duplication · FLT3 internal tandem duplication (FLT3-ITD) · oral FLT3 inhibitor · Newly diagnosed acute myeloid leukemia · Relapsed/refractory acute myeloid leukemia · Complete remission (CR) · Complete remission with incomplete hematologic recovery (CRi) · CRi · Measurable residual disease (MRD) · MRD negativity · relapse-free survival · Overall survival · morphologic leukemia-free state · myelosuppression · maximum tolerated dose · phase I/II trial

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Acute Myeloid Leukemia Research Papers, Class of 2026. https://pri.pepkio.com/top-papers/acute-myeloid-leukemia-research/2026. Accessed 2026-07-31.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```